Cover Image

MRI/US fusion prostate biopsy: Our initial experience

Vito Lacetera, Bernardo Cervelli, Antonio Cicetti, Giuliana Gabrielloni, Michele Montesi, Roberto Morcellini, Gianni Parri, Emilio Recanatini, Gianluca Giglioni, Andrea Benedetto Galosi, Valerio Beatrici
  • Bernardo Cervelli
    Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro, Italy
  • Antonio Cicetti
    Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro, Italy
  • Giuliana Gabrielloni
    Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro, Italy
  • Michele Montesi
    Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro, Italy
  • Roberto Morcellini
    Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro, Italy
  • Gianni Parri
    Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro, Italy
  • Emilio Recanatini
    Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro, Italy
  • Gianluca Giglioni
    Clinica Urologica, Università Politecnica delle Marche, Azienda Ospedaliera Ospedali Runiti, Ancona, Italy
  • Andrea Benedetto Galosi
    Clinica Urologica, Università Politecnica delle Marche, Azienda Ospedaliera Ospedali Runiti, Ancona, Italy
  • Valerio Beatrici
    Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro, Italy

Abstract

Aim: The objective of this study is to present our initial experience with magnetic resonance imaging/ultrasound (MRI/US) fusion biopsy using the Koelis Trinity device after the first consecutive 59 patients. Materials and methods: 59 consecutive patients with suspected prostate cancer (PCA) underwent prostate biopsy using Trinity Koelis® (Koelis, Grenoble, France). We divided the patients into 2 groups: patients with a previous negative mapping underwent to a MRI/US fusion re-biopsy (Group A); and biopsy-naïve patients who underwent to a first stereotactic 3-D mapping of the prostate (Group B). Group A (22 patients):mean age 64 years (CI 48-73), mean PSA = 7.7 ng/ml (CI 4.2- 9.9); mean prostate volume 55 ml(CI 45-82), Digital Rectal Examination (DRE) positive in 2/22, number of lesions detected by MRI 1.4, mean cores from each MRI target lesion 3 (CI 2-5), mean total cores 15 ( CI 12-19). Group B (37 patients): mean age 66 years (CI 49-77), mean PSA= 4.7 (3.2- 7.9); mean prostate volume 45 ml (33-67), DRE positive in 5/37, mean total cores 14 ( CI 10-16) Results: In Group A 10/22 patients were positive for PCA (overall detection rate of 45.5%): 6 PCA were detected by target biopsy and 4 cancer by random biopsy. Significant prostate cancer (defined as the presence of Gleason pattern 4) was detected in 4/10 patients (Significant PCA detection rate of 40%) and all significant PCA were detected by MRI target biopsy. All PCA detected by random biopsy had Gleason score 3 + 3 = 6. In Group B (biopsy naïve patients) 14/37 patients were positive for PCA (overall detection rate of 37.8%), Significant prostate cancer was detected in 5/14 patients (Significant PCA detection rate of 35,7%). No significant side effects were recorded. Conclusions: Our overall detection rate was 45.5% and 37.8% in Group A (patients with previous negative biopsy and persistent suspicion of PCA) and in Group B (biopsy naïve patients) respectively; clinical significant PCA detection rate was respectively 40% and 35.7%. These results are similar to current literature and promising for the future. We believe that using platforms of co-registered MRI/US fusion biopsy can potentially improve risk stratification and reduces understaging, undergrading and the need for repeat biopsies in biopsy naïve patients (using a stereotactic first mapping) and in patients with previous negative biopsy and persistent suspicion of PCA ( using a second MRI/US fusion biopsy).

Keywords

MRI/US fusion biopsy; Prostate cancer; Prostate biopsy

Full Text:

PDF
Submitted: 2017-01-10 13:51:46
Published: 2016-12-30 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
1409

Views:
PDF
658

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2017 Vito Lacetera, Bernardo Cervelli, Antonio Cicetti, Giuliana Gabrielloni, Michele Montesi, Roberto Morcellini, Gianni Parri, Emilio Recanatini, Gianluca Giglioni, Andrea Benedetto Galosi, Valerio Beatrici

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185